CFO
RYTM icon

CVA Family Office’s Rhythm Pharmaceuticals RYTM Stock Holding History

CVA Family Office’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.44K Buy
28
+16
+133% +$1.56K ﹤0.01% 1466
2025
Q4 		$1.28K Hold
12
– – ﹤0.01% 1060
2025
Q3 		$1.21K Hold
12
– – ﹤0.01% 1097
2025
Q2 		$758 Hold
12
– – ﹤0.01% 1140
2025
Q1 		$636 Hold
12
– – ﹤0.01% 1180
2024
Q4 		$672 Hold
12
– – ﹤0.01% 1161
2024
Q3 		$629 Hold
12
– – ﹤0.01% 1148
2024
Q2 		$493 Buy
+12
New +$479 ﹤0.01% 1218

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

CVA Family Office's RYTM Position: Q1 2026 in Review

CVA Family Office increased its Rhythm Pharmaceuticals (RYTM) stake by 133% in Q1 2026, buying an estimated $1.56K and bringing the position to 28 shares worth $2.44K. The position accounts for ﹤0.01% of the portfolio, ranked #1466.

CVA Family Office first reported a position in RYTM in Q2 2024 and has held it in 8 quarters since. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • CVA Family Office held 28 shares of Rhythm Pharmaceuticals worth $2.44K as of Q1 2026.
  • CVA Family Office bought 16 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $1.56K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of CVA Family Office's portfolio in Q1 2026, its #1466 holding.
  • CVA Family Office first reported a position in Rhythm Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on CVA Family Office's 13F filing for Q1 2026, filed 29 Apr 2026.